Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
60
Participants
Timeline
Start Date
June 30, 2002
Primary Completion Date
January 31, 2007
Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Interventions
DRUG
imatinib mesylate
Given PO
OTHER
laboratory biomarker analysis
Correlative studies
Trial Locations (1)
19103
Gynecologic Oncology Group, Philadelphia
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00041041 - Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter